Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Development of a Biomarker of Efficacy of Vedolizumab (EnTyvio®) in Patients With ulcErative ColiTis (DETECT)

NCT02878083 is registered in ClinicalTrials.gov with Nantes University Hospital as lead sponsor.

NCT NCT02878083
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02878083 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Development of a Biomarker of Efficacy of Vedolizumab (EnTyvio®) in Patients With ulcErative ColiTis (DETECT)
Lead sponsor
Nantes University Hospital
Phase
Not applicable
Overall status
Terminated
Start date
January 11, 2017
Completion date
January 1, 2021
Enrollment
19 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis